Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BLR013
MIFTS: 43

Biliary Tract Cancer

Categories: Cancer diseases, Liver diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Biliary Tract Cancer

About this section

MalaCards integrated aliases for Biliary Tract Cancer:

Name: Biliary Tract Cancer 20 54

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Liver diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

ICD10 32 C24.9
Sources

Summaries for Biliary Tract Cancer

About this section
MalaCards based summary : Biliary Tract Cancer is related to gallbladder cancer and intrahepatic cholangiocarcinoma. An important gene associated with Biliary Tract Cancer is SMAD4 (SMAD Family Member 4), and among its related pathways/superpathways are HIV Life Cycle and PAK Pathway. The drugs Gemcitabine and Capecitabine have been mentioned in the context of this disorder. Affiliated tissues include pancreas, liver and lymph node, and related phenotypes are Decreased mitotic index and digestive/alimentary

Wikipedia : 73 Cholangiocarcinoma, also known as bile duct cancer, is a type of cancer that forms in the bile ducts.... more...

Sources

Related Diseases for Biliary Tract Cancer

About this section

Diseases related to Biliary Tract Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 208)
# Related Disease Score Top Affiliating Genes
1 gallbladder cancer 31.6 MLH1 ERBB2 EGFR
2 intrahepatic cholangiocarcinoma 31.2 SMAD4 MUC4 ERBB2 EGFR
3 cholangiocarcinoma 30.8 SMAD4 MUC4 MET ERBB2 EGFR
4 bile duct cancer 30.7 SMAD4 MUC4 MLH1 MET ERBB2 EGFR
5 gallbladder adenocarcinoma 30.4 ERBB2 EGFR
6 pancreatic ductal adenocarcinoma 30.2 SMAD4 ERBB2 EGFR
7 gastroesophageal adenocarcinoma 29.7 MET ERBB2 EGFR
8 gastric adenocarcinoma 29.4 SMAD4 MLH1 ERBB2
9 adenoma 29.2 TGFBR2 SMAD4 MLH1
10 colon adenocarcinoma 29.2 SMAD4 MLH1 ERBB2 EGFR
11 pancreatic adenocarcinoma 29.0 TGFBR2 SMAD4 MUC4 MET ERBB2 EGFR
12 adenocarcinoma 28.5 TGFBR2 SMAD4 MUC4 MLH1 MET ERBB2
13 pancreatic cancer 28.3 TGFBR2 SMAD4 MUC4 MLH1 MET ERBB2
14 neutropenia 10.8
15 ampulla of vater cancer 10.6
16 cholangitis 10.6
17 thrombocytopenia 10.6
18 gallbladder disease 1 10.5
19 exanthem 10.5
20 biliary tract disease 10.4
21 bladder cancer 10.4
22 cholangitis, primary sclerosing 10.4
23 mucositis 10.4
24 diarrhea 10.4
25 sclerosing cholangitis 10.4
26 cholecystitis 10.4
27 cholelithiasis 10.3
28 convulsions, familial infantile, with paroxysmal choreoathetosis 10.3
29 obstructive jaundice 10.3
30 constipation 10.3
31 peripheral nervous system disease 10.3
32 wilms tumor 1 10.2
33 bilirubin metabolic disorder 10.2
34 neuropathy 10.2
35 stomatitis 10.2
36 mammary analogue secretory carcinoma 10.2 MUC4 EGFR
37 breast scirrhous carcinoma 10.2 ERBB2 EGFR
38 breast metaplastic carcinoma 10.2 ERBB2 EGFR
39 submandibular gland cancer 10.2 ERBB2 EGFR
40 breast malignant phyllodes tumor 10.2 ERBB2 EGFR
41 progesterone-receptor negative breast cancer 10.2 ERBB2 EGFR
42 paronychia 10.2 ERBB2 EGFR
43 apocrine adenocarcinoma 10.2 ERBB2 EGFR
44 ethmoid sinus adenocarcinoma 10.2 ERBB2 EGFR
45 primary peritoneal carcinoma 10.2 ERBB2 EGFR
46 synchronous bilateral breast carcinoma 10.2 ERBB2 EGFR
47 microglandular adenosis 10.1 ERBB2 EGFR
48 lung non-squamous non-small cell carcinoma 10.1 ERBB2 EGFR
49 doxorubicin induced cardiomyopathy 10.1 MET EGFR
50 gastroesophageal junction adenocarcinoma 10.1 ERBB2 EGFR

Graphical network of the top 20 diseases related to Biliary Tract Cancer:



Diseases related to Biliary Tract Cancer
Sources

Symptoms & Phenotypes for Biliary Tract Cancer

About this section

GenomeRNAi Phenotypes related to Biliary Tract Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased mitotic index GR00110-A-0 8.32 TGFBR2

MGI Mouse Phenotypes related to Biliary Tract Cancer:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 10.1 DPYD EGFR ERBB2 LGR4 MET MLH1
2 cellular MP:0005384 10.07 EGFR ERBB2 LGR4 MET MLH1 SMAD4
3 endocrine/exocrine gland MP:0005379 10 EGFR ERBB2 LGR4 MET MLH1 SMAD4
4 immune system MP:0005387 9.98 DPYD EGFR LGR4 MET MLH1 SMAD4
5 embryo MP:0005380 9.95 EGFR ERBB2 LGR4 MET SMAD4 TGFBR2
6 craniofacial MP:0005382 9.91 EGFR ERBB2 MET SMAD4 TGFBR2
7 integument MP:0010771 9.88 EGFR ERBB2 LGR4 MLH1 SMAD4 TGFBR2
8 liver/biliary system MP:0005370 9.77 EGFR LGR4 MET SMAD4 TGFBR2
9 neoplasm MP:0002006 9.73 EGFR ERBB2 MET MLH1 SMAD4 TGFBR2
10 muscle MP:0005369 9.72 EGFR ERBB2 MET SMAD4 TGFBR2
11 renal/urinary system MP:0005367 9.55 EGFR LGR4 MET SMAD4 TGFBR2
12 reproductive system MP:0005389 9.43 DPYD EGFR ERBB2 LGR4 MLH1 SMAD4
13 respiratory system MP:0005388 9.02 EGFR ERBB2 MET MLH1 TGFBR2
Sources

Drugs & Therapeutics for Biliary Tract Cancer

About this section

Drugs for Biliary Tract Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 93)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 3 95058-81-4 60750
2
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
3
Durvalumab Approved, Investigational Phase 3 1428935-60-7
4
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
5
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
6
Fluorouracil Approved Phase 3 51-21-8 3385
7
leucovorin Approved Phase 3 58-05-9 6006
8
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
9
Cediranib Investigational Phase 2, Phase 3 288383-20-0 9933475
10 Protein Kinase Inhibitors Phase 2, Phase 3
11 Antibiotics, Antitubercular Phase 3
12 Anti-Bacterial Agents Phase 3
13 Hematinics Phase 3
14 Antiemetics Phase 3
15 Emetics Phase 3
16 Antineoplastic Agents, Immunological Phase 3
17 Tubulin Modulators Phase 3
18 Antimitotic Agents Phase 3
19 Albumin-Bound Paclitaxel Phase 3
20 Immunosuppressive Agents Phase 3
21 Immunologic Factors Phase 3
22 Vitamin B9 Phase 3
23 Antidotes Phase 3
24 Nutrients Phase 3
25 Trace Elements Phase 3
26 Micronutrients Phase 3
27 Vitamin B Complex Phase 3
28 Vitamins Phase 3
29 Folate Phase 3
30 Protective Agents Phase 3
31
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
32
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
33
Epinephrine Approved, Vet_approved Phase 2 51-43-4 5816
34
Racepinephrine Approved Phase 2 329-65-7 838
35
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
36
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
37
Panitumumab Approved, Investigational Phase 2 339177-26-3 50070211
38
Trametinib Approved Phase 2 871700-17-3 11707110
39
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
40
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
41
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
42
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
43
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
44
Rucaparib Approved, Investigational Phase 2 283173-50-2 9931954
45
Lenvatinib Approved, Investigational Phase 2 417716-92-8
46
Pancrelipase Approved, Investigational Phase 2 53608-75-6
47
Tegafur Approved, Investigational Phase 2 17902-23-7 5386
48
Olaparib Approved Phase 2 763113-22-0 23725625
49
ramucirumab Approved, Investigational Phase 2 947687-13-0
50
Ipilimumab Approved Phase 2 477202-00-9

Interventional clinical trials:

(show top 50) (show all 162)
# Name Status NCT ID Phase Drugs
1 The Effect of Individualized Precision Therapy Programs in Patients With Biliary Tract Cancer Recruiting NCT02943031 Phase 4
2 A Non-Randomized, Multi-Center, Prospective, Single Arm Clinical Study of the X-SUIT NIR® Covered Biliary Metallic Stent for Palliation of Malignant Strictures in the Biliary Tree Via Endoscopic Approach Unknown status NCT01899976 Phase 3
3 A Phase III, Randomised, Multicentre Open-label Study of Active Symptom Control (ASC) Alone or ASC With Oxaliplatin/ 5F-U Chemotherapy for Patients With Locally Advanced/ Metastatic Biliary Tract Cancers Previously Treated With Cisplatin/ Gemcitabine Chemotherapy. Completed NCT01926236 Phase 3 L-folinic acid;5 FU;Oxaliplatin
4 Randomized Phase III Trial Comparing Gemcitabine/Cisplatin/S-1 With Gemcitabine/Cisplatin for Unresectable Biliary Tract Cancer Completed NCT02182778 Phase 3 Gemcitabine/Cisplatin;Gemcitabine/Cisplatin /S-1
5 A Randomised Clinical Trial Evaluating Adjuvant Chemotherapy With Capecitabine Compared to Expectant Treatment Alone (Observation) Following Surgery for Biliary Tract Cancer Completed NCT00363584 Phase 3 capecitabine
6 Randomised Phase II Trial of Cediranib (AZD2171) Versus Placebo in Addition to Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract Cancers Completed NCT00939848 Phase 2, Phase 3 gemcitabine;cisplatin;Placebo;cisplatin;cediranib;gemcitabine
7 A Phase III Open-Label, Multi-Centre, Randomized Study Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer Recruiting NCT04163900 Phase 3 NUC-1031;Gemcitabine;Cisplatin
8 Gemcitabine and Oxaliplatin With or Without KN035 for Biliary Tract Cancer: a Randomised, Open-label, Parallel-group, Multicenter Phase III Study Recruiting NCT03478488 Phase 3 KN035 plus Gemcitabine & oxaliplatin;Gemcitabine & oxaliplatin
9 A Randomized, Open, Multi-center Phase IIb/III Clinical Study to Assess the Efficacy and Safety of Surufatinib Compared to Capecitabine in Advanced or Metastatic Biliary Tract Carcinoma (BTC) Patients Recruiting NCT03873532 Phase 2, Phase 3 Surufatinib;Capecitabine
10 A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer Recruiting NCT04066491 Phase 2, Phase 3 Bintrafusp alfa;Placebo;Gemcitabine;Cisplatin
11 Adjuvant Chemotherapy With Gemcitabine and Capecitabine Compared to Capecitabine for Biliary Tract Cancer After Curative Resection Recruiting NCT03779035 Phase 3 Gemcitabine;Capecitabine
12 A Phase III Randomized, Double-Blind Placebo Controlled, Multi-Regional, International Study of Durvalumab in Combination With Gemcitabine Plus Cisplatin Versus Placebo in Combination With Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers Recruiting NCT03875235 Phase 3 Durvalumab;Placebo
13 A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers Recruiting NCT03768414 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Nab-paclitaxel
14 A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Varlitinib Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer as Second Line Systemic Therapy Active, not recruiting NCT03093870 Phase 2, Phase 3 Varlitinib;Capecitabine;Placebo (for Varlitinib)
15 A Randomized, Multi-center Phase III Trial of Adjuvant Chemotherapy With Gemcitabine and Capecitabine Compared to Capecitabine Alone in Curatively Resected Biliary Tract Cancer Not yet recruiting NCT04401709 Phase 3 Gemcitabine/Capecitabine;Capecitabine
16 A Phase 3 Multicenter, Open Label, Randomized Study of XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors Not Amenable to Conventional Surgery Terminated NCT00090025 Phase 3 becatecarin;5-Fluorouracil Plus Leucovorin
17 A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507 in Subjects With Cancer Withdrawn NCT02597465 Phase 3 SPARC1507;Reference1507
18 A Multicenter Phase II Trial of Preoperative Chemotherapy With Gemcitabine/ Cisplatin /S-1 (GCS) for Biliary Tract Cancers With Lymph Node Metastasis Diagnosed by Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Unknown status NCT01821248 Phase 2 Gemcitabine, Cisplatin, S-1
19 Phase II Exploratory Study of S-1 Combined With Oxaliplatin Sequential S-1 Single-agent First-line Treatment of Unresectable Metastatic or Locally Advanced Biliary System, Periampullary Cancer and Pancreatic Cancer Unknown status NCT01811277 Phase 2 SOX sequential S-1
20 An Pilot Study of S-1 Combined With Oxaliplatin for First-line Treatment of Unresectable, Metastatic or Locally Advanced Biliary Tract Cancer or Ampullary Adenocarcinoma Unknown status NCT01180153 Phase 2 S-1 oxaliplatin
21 Multicenter Phase II Study of Docetaxel and Oxaliplatin Combination in Patients With Locally Advanced or Metastatic Biliary Tract Cancer Unknown status NCT01234051 Phase 2 Docetaxel, Oxaliplatin
22 Multicenter Phase II Study of Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) in Patients With Locally Advanced or Metastatic Biliary Tract Cancer Unknown status NCT01494363 Phase 2 Fluorouracil;Leucovorin;Oxaliplatin;Irinotecan
23 Phase II Study of Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancer Unknown status NCT03144856 Phase 2 Apatinib
24 A Single-arm, Open-label and Exploratory Clinical Study of PD-1 Monoclonal Antibody SHR-1210 in Combination With GEMOX (Gemcitabine Combined Oxaliplatin) in Patients With Advanced Biliary Tract Cancer Unknown status NCT03486678 Phase 2 SHR-1210+GEMOX
25 Phase II Trial of Infusional 5 FLUOROURACIL, LEUCOVORIN, OXALIPLATIN AND IRINOTECAN (FOLFIRINOX) in First Line Treatment of Advanced Biliary Tract Cancers Unknown status NCT03291899 Phase 2
26 A Pilot Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Patients With Advanced Unresectable or Metastatic Biliary Tract Cancers Unknown status NCT03311789 Phase 1, Phase 2 PD-1 inhibitor + Gemcitabine + Cisplatin
27 GAMBIT Trial: A Randomized,Non-comparative, Open-label Clinical Trial Evaluating Cisplatin Plus Irinotecan in the Treatment of Gallbladder or Biliary Tract Cancer Unknown status NCT01859728 Phase 2 Irinotecan;Cisplatin;Cisplatin;Gemcitabine
28 Phase II Study of S-1 in Combination With Oxaliplatin and Irinotecan in Patients With Advanced, Recurrent or Metastatic Biliary Tract Cancer Unknown status NCT02527824 Phase 2 Oxaliplatin, Irinotecan, S-1
29 A Randomized Phase II Study of Gemcitabine Plus Oxaliplatin (GEMOX) With or Without Cetuximab in Locally Advanced and Metastatic Biliary Tract Cancer (BTC) Completed NCT01267344 Phase 2 gemcitabine, oxaliplatin;cetuximab, gemcitabine, oxaliplatin
30 A Randomized Phase II Trial of Second Line Therapy in Advanced Biliary Tract Cancer: Capecitabine or Capecitabine Plus Mitomycin C Completed NCT01530503 Phase 2 capecitabine and mitomycin;Capecitabine
31 A Randomized Study of Gemcitabine/Cisplatin Versus Single-Agent Gemcitabine in Patients With Biliary Tract Cancer Completed NCT00380588 Phase 2 gemcitabine;cisplatin
32 Phase II Study of Salvage mFOLFOX(5-fluorouracil, Leucovorin, Oxaliplatin) in Patients With Unresectable Biliary Tract Cancer (BTC) Who Had Failed Gemcitabine Completed NCT01127555 Phase 2 5-fluorouracil, leucovorin, oxaliplatin
33 Phase II Trial of Modified FOLFIRINOX in Patients With Metastatic Biliary Tract Cancer After Failure of Gemcitabine/Cisplatin Chemotherapy Completed NCT03778593 Phase 2 5-Fluorouracil;Leucovorin;Irinotecan;Oxaliplatin;5% dextrose water
34 Phase II Study of Gemcitabine, Oxaliplatin in Combination With Bevacizumab (Avastin) in Unresectable or Metastatic Biliary Tract and Gallbladder Cancer Completed NCT00361231 Phase 2 Bevacizumab;Gemcitabine;Oxaliplatin
35 Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma Completed NCT02346032 Phase 2 refametinib
36 A Phase II, Single-arm, Open-label, Multicenter Study to Assess the Efficacy and Safety of Surufatinib as a Second-line Treatment in Patients With Surgically Unresectable or Metastatic Biliary Tract Carcinoma Completed NCT02966821 Phase 2 Surufatinib
37 Phase II Study of Nab-paclitaxel Plus S-1 in First-line Treatment of Advanced Biliary Tract Adenocarcinoma Completed NCT03830606 Phase 2 Nab-paclitaxel,S-1
38 Phase II Study of Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Biliary Tract and Gallbladder Cancer Completed NCT00142480 Phase 2 Capecitabine;Oxaliplatin;Bevacizumab
39 Phase Ib Study of MEK162 in Combination With Capecitabine in Gemcitabine-pretreated Advanced Biliary Tract Cancer Completed NCT02773459 Phase 1, Phase 2 MEK162+capecitabine
40 Randomized Phase II Study of Gemcitabine Versus S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer Completed NCT01815307 Phase 2 Gemcitabine;S-1
41 A Phase 2 Study of AZD6244 in Biliary Cancers Completed NCT00553332 Phase 2 selumetinib
42 Phase II Study of Gemcitabine, Oxaliplatin in Combination With Panitumumab in Kras/B-raf Wild-Type Unresectable or Metastatic Biliary Track and Gallbladder Cancer Completed NCT01308840 Phase 2 Panitumumab;oxaliplatin;gemcitabine
43 An Open-Label, Multicenter Phase 2 Study of E7080/ LENVIMA (Lenvatinib Mesylate) in Subjects With Unresectable Biliary Tract Cancer Who Failed Gemcitabine-based Combination Chemotherapy Completed NCT02579616 Phase 2 Lenvatinib
44 Irinotecan, Gemcitabine, Chemotherapy for Biliary Tract Cancer Completed NCT00832689 Phase 2 Irinotecan and Gemcitabine
45 The Feasibility Study of Oral Rehydration Therapy for Short Hydration in Chemotherapy With Cisplatin Plus Gemcitabine for Biliary Tract Cancer Completed NCT01917617 Phase 2 Gemcitabine , Cisplatin, Oral Rehydration Solution (ORS);Gemcitabine , Cisplatin
46 A Phase 2A, Single Arm, Multicentre, Study of Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer Who Progressed on at Least 1 Line of Systemic Therapy Completed NCT03231176 Phase 2 Varlitinib;Capecitabine
47 Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer Completed NCT02433639 Phase 2 TH-302 monotherapy
48 A Randomized, Multicentre, Phase II, Parallel-Group Trial of Vandetanib Monotherapy or Vandetanib in Combination With Gemcitabine Versus Gemcitabine Plus Vandetanib Matching Placebo in Subjects With Advanced Biliary Tract Cancer (Gallbladder Cancer, Cancer of the Extrahepatic Bile Duct, Intrahepatic Cholangiocarcinoma and Ampullary Carcinoma) Completed NCT00753675 Phase 2 ZD6474, Vandetanib;ZD6474, Vandetanib;Gemcitabine;Placebo matching ZD6474
49 A Study of S-1 in Combination With Gemcitabine as First-Line Treatment in Patients With Advanced Biliary Tract Cancer Completed NCT02425137 Phase 2 S-1/Gemcitabine
50 Phase I/II Study of Gemcitabine/Cisplatin/S-1(GCS) Combination Therapy for Patients With Advanced Biliary Tract Cancer Completed NCT01284413 Phase 1, Phase 2 S-1, Gemcitabine, Cisplatin

Search NIH Clinical Center for Biliary Tract Cancer

Sources

Genetic Tests for Biliary Tract Cancer

About this section
Sources

Anatomical Context for Biliary Tract Cancer

About this section

MalaCards organs/tissues related to Biliary Tract Cancer:

40
Pancreas, Liver, Lymph Node, Endothelial, Neutrophil, Skeletal Muscle, Testis
Sources

Publications for Biliary Tract Cancer

About this section

Articles related to Biliary Tract Cancer:

(show top 50) (show all 1437)
# Title Authors PMID Year
1
EGFR and HER2 expression in advanced biliary tract cancer. 61 54
19777609 2009
2
Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells. 61 54
19509244 2009
3
Thymidylate synthase and dihydropyrimidine dehydrogenase are upregulated in pancreatic and biliary tract cancers. 54 61
19571608 2009
4
MUC4 and MUC5AC are highly specific tumour-associated mucins in biliary tract cancer. 61 54
18475301 2008
5
[Expressions and clinical significances of c-met, c-erbB-2, COX-2, and IL-6 in the biliary tract cancers]. 54 61
18159174 2007
6
A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as first-line treatment in patients with advanced biliary cancers. 61 54
17364234 2007
7
Restoration of RUNX3 enhances transforming growth factor-beta-dependent p21 expression in a biliary tract cancer cell line. 54 61
17470130 2007
8
CPT-11 (SN-38) chemotherapy may be selectively applicable to biliary tract cancer with low hMLH1 expression. 61 54
17465213 2007
9
Deficient expression of the DPD gene is caused by epigenetic modification in biliary tract cancer cells, and induces high sensitivity to 5-FU treatment. 61 54
16820886 2006
10
Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib. 54 61
16926628 2006
11
K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China. 61 54
12374683 2002
12
Allelotype analysis of the PTEN, Smad4 and DCC genes in biliary tract cancer. 54 61
12168833 2002
13
Infrequent microsatellite instability in biliary tract cancer. 54 61
11223838 2001
14
Significance of c-erbB-2 expression in normal and neoplastic epithelium of biliary tract. 61 54
7645925 1995
15
Serum levels of c-erbB-2 protein in digestive diseases. 61 54
7528080 1994
16
Deciphering the impact of missense mutations on structure and dynamics of SMAD4 protein involved in pathogenesis of gall bladder cancer. 61
32151199 2021
17
Prognosis of Primary Sclerosing Cholangitis According to Age of Onset. 61
33811469 2021
18
Recurrent cholangiocarcinoma with long-term survival by multimodal treatment: A case report. 61
33732458 2021
19
A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08). 61
33210382 2021
20
Issues to be considered to address the future liver remnant prior to major hepatectomy. 61
32894345 2021
21
Role of adjuvant and neoadjuvant therapy for resectable biliary tract cancer. 61
33793366 2021
22
[Conversion therapy of biliary tract cancer from the perspective of tumor heterogeneity]. 61
33706442 2021
23
Next-generation sequencing-guided molecular-targeted therapy and immunotherapy for biliary tract cancers. 61
33095329 2021
24
Association between the confluent form of pancreatic and bile duct and histopathological findings in pancreaticobiliary maljunction: A case series study. 61
33717474 2021
25
Prevalence and associated factors of orphan symptoms in advanced cancer patients: a multicenter observational study. 61
33725175 2021
26
Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study). 61
33106918 2021
27
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. 61
33798493 2021
28
Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer. 61
33730723 2021
29
Tumor Infiltrating Neutrophils Are Frequently Found in Adenocarcinomas of the Biliary Tract and Their Precursor Lesions with Possible Impact on Prognosis. 61
33806804 2021
30
Cholangiocarcinoma: shedding light on the most promising drugs in clinical development. 61
33645382 2021
31
Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: Leading the way for precision medicine in biliary tract cancer [BTC]? 61
33678096 2021
32
Causal effects of gallstone disease on risk of gastrointestinal cancer in Chinese. 61
33772150 2021
33
The evolving landscape of systemic treatment for advanced hepatocellular carcinoma and biliary tract cancer. 61
33799005 2021
34
Palliative endoscopic retrograde biliary drainage for malignant biliary obstruction in Korea: A nationwide assessment. 61
33723093 2021
35
WEE1 inhibition reverses trastuzumab resistance in HER2-positive cancers. 61
33723720 2021
36
Outcomes in older patients with biliary tract cancer. 61
32209312 2021
37
FGFR Inhibitors in Elderly Patients with Advanced Biliary Tract Cancer: An Unsolved Issue. 61
33787429 2021
38
Angiogenesis in biliary tract cancer: targeting and therapeutic potential. 61
33491502 2021
39
Investigational PARP inhibitors for the treatment of biliary tract cancer: spotlight on preclinical and clinical studies. 61
33660569 2021
40
The global, regional, and national burden of gallbladder and biliary tract cancer and its attributable risk factors in 195 countries and territories, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study 2017. 61
33748947 2021
41
Clinical Trial of a Cancer Vaccine Targeting VEGF and KIF20A in Advanced Biliary Tract Cancer. 61
33788741 2021
42
SEOM clinical guidelines for pancreatic and biliary tract cancer (2020). 61
33660222 2021
43
Blood tests predict the therapeutic prognosis of anti-PD-1 in advanced biliary tract cancer. 61
33724548 2021
44
Novel approaches for the management of biliary tract cancer: today and tomorrow. 61
33626999 2021
45
Advanced Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin (GEMCIS) and Novel Inflammatory Markers. 61
32495108 2021
46
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer. 61
33645367 2021
47
Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action. 61
32954856 2021
48
Tumour-Agnostic Therapy for Pancreatic Cancer and Biliary Tract Cancer. 61
33562094 2021
49
A Series of Biliary Tract Cancer With Coexistent Non-biliary Second Malignancy From Sub-Himalayan Region of India. 61
33758710 2021
50
Surgical oncologist and liver cancer expert Dr. Tim Pawlik on the potential of pharmacological and surgical approaches in biliary tract cancer. 61
33455466 2021
Sources

Variations for Biliary Tract Cancer

About this section
Sources

Expression for Biliary Tract Cancer

About this section
Search GEO for disease gene expression data for Biliary Tract Cancer.
Sources

Pathways for Biliary Tract Cancer

About this section

Pathways related to Biliary Tract Cancer according to GeneCards Suite gene sharing:

(show all 31)
# Super pathways Score Top Affiliating Genes
1
HIV Life Cycle 65
Show member pathways
 13.45 TGFBR2 SMAD4 MUC4 MET ERBB2 EGFR
2
PAK Pathway 63
Show member pathways
 13.05 TGFBR2 SMAD4 MET ERBB2 EGFR
3
Regulation of lipid metabolism Insulin signaling-generic cascades 23
Show member pathways
 12.67 TGFBR2 MET ERBB2 EGFR
4
Endometrial cancer 36
Show member pathways
 12.58 TGFBR2 SMAD4 MLH1 ERBB2 EGFR
5
MAPK signaling pathway 36 1
12.52 TGFBR2 MET ERBB2 EGFR
6
Pathways in cancer 36
12.46 TGFBR2 SMAD4 MLH1 MET ERBB2 EGFR
7
Gastric cancer 36
Show member pathways
 12.3 TGFBR2 SMAD4 MLH1 MET ERBB2 EGFR
8
mTOR signaling pathway (KEGG) 36
Show member pathways
 12.28 MET LGR4 ERBB2 EGFR
9
Calcium signaling pathway 36
12.19 MET ERBB2 EGFR
10
Apoptosis Pathway 69
Show member pathways
 12.18 TGFBR2 MET ERBB2 EGFR
11
Translation Non-genomic (rapid) action of Androgen Receptor 23
Show member pathways
 12.12 TGFBR2 ERBB2 EGFR
12
Proteoglycans in cancer 36
12.11 MET ERBB2 EGFR
13
Integrated Breast Cancer Pathway 1
11.94 TGFBR2 SMAD4 EGFR
14
Colorectal Cancer Metastasis 63
11.92 TGFBR2 SMAD4 MLH1 EGFR
15
Tyrosine Kinases / Adaptors 4
11.91 MET ERBB2 EGFR
16
FoxO signaling pathway 36
Show member pathways
 11.87 TGFBR2 SMAD4 EGFR
17
TGF-beta Signaling Pathway (WikiPathways) 1
11.84 TGFBR2 SMAD4 MET
18
Direct p53 effectors 1
11.82 MLH1 MET EGFR
19
Development_TGF-beta receptor signaling 23
11.53 TGFBR2 SMAD4 ERBB2
20
Central carbon metabolism in cancer 36
11.5 MET ERBB2 EGFR
21
IL-2 Gene Expression in Activated and Quiescent T-Cells 63
Show member pathways
 11.31 TGFBR2 SMAD4 ERBB2 EGFR
22
Alzheimers Disease Pathway 63
11.3 ERBB2 EGFR
23
Signaling events mediated by TCPTP 1
Show member pathways
 11.27 MET EGFR
24
Stabilization and expansion of the E-cadherin adherens junction 1
11.24 MET EGFR
25
Adherens junction 36
11.2 TGFBR2 SMAD4 MET ERBB2 EGFR
26
Arf6 signaling events 1
11.16 MET EGFR
27
ALK1 signaling events 1
Show member pathways
 11.05 TGFBR2 SMAD4
28
a6b1 and a6b4 Integrin signaling 1
11.04 MET ERBB2 EGFR
29
Hypothesized Pathways in Pathogenesis of Cardiovascular Disease 1
11.01 TGFBR2 SMAD4
30
NTHi-Induced Signaling 63
10.91 TGFBR2 SMAD4
31
Extracellular vesicle-mediated signaling in recipient cells 1
10.5 TGFBR2 SMAD4 MET ERBB2 EGFR
Sources

GO Terms for Biliary Tract Cancer

About this section

Cellular components related to Biliary Tract Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.63 TGFBR2 MUC4 MET LGR4 ERBB2 EGFR
2 basal plasma membrane GO:0009925 9.13 MET ERBB2 EGFR
3 receptor complex GO:0043235 8.92 TGFBR2 MET ERBB2 EGFR

Biological processes related to Biliary Tract Cancer according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 phosphorylation GO:0016310 9.85 TGFBR2 MET ERBB2 EGFR
2 MAPK cascade GO:0000165 9.76 MET ERBB2 EGFR
3 protein phosphorylation GO:0006468 9.76 TGFBR2 MET ERBB2 EGFR
4 positive regulation of protein kinase B signaling GO:0051897 9.61 MET ERBB2 EGFR
5 cellular response to epidermal growth factor stimulus GO:0071364 9.59 ERBB2 EGFR
6 hair follicle development GO:0001942 9.58 LGR4 EGFR
7 peptidyl-tyrosine phosphorylation GO:0018108 9.58 MET ERBB2 EGFR
8 gastrulation GO:0007369 9.57 TGFBR2 SMAD4
9 ventricular septum morphogenesis GO:0060412 9.56 TGFBR2 SMAD4
10 regulation of cell motility GO:2000145 9.54 ERBB2 EGFR
11 regulation of ERK1 and ERK2 cascade GO:0070372 9.52 ERBB2 EGFR
12 digestive tract development GO:0048565 9.51 TGFBR2 LGR4
13 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.5 MET ERBB2 EGFR
14 ERBB2 signaling pathway GO:0038128 9.49 ERBB2 EGFR
15 outflow tract septum morphogenesis GO:0003148 9.48 TGFBR2 SMAD4
16 wound healing GO:0042060 9.43 TGFBR2 ERBB2 EGFR
17 secondary palate development GO:0062009 9.37 TGFBR2 SMAD4
18 positive regulation of kinase activity GO:0033674 9.33 MET ERBB2 EGFR
19 negative regulation of ERBB signaling pathway GO:1901185 8.96 ERBB2 EGFR
20 cellular response to growth factor stimulus GO:0071363 8.8 TGFBR2 ERBB2 EGFR

Molecular functions related to Biliary Tract Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.8 TGFBR2 MLH1 MET ERBB2 EGFR
2 kinase activity GO:0016301 9.67 TGFBR2 MET ERBB2 EGFR
3 nucleotide binding GO:0000166 9.63 TGFBR2 MLH1 MET ERBB2 EGFR DPYD
4 protein kinase activity GO:0004672 9.62 TGFBR2 MET ERBB2 EGFR
5 transmembrane signaling receptor activity GO:0004888 9.61 LGR4 ERBB2 EGFR
6 protein tyrosine kinase activity GO:0004713 9.43 MET ERBB2 EGFR
7 protein phosphatase binding GO:0019903 9.13 MET ERBB2 EGFR
8 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.8 MET ERBB2 EGFR
Sources

Sources for Biliary Tract Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....